By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018, UNC Lineberger Comprehensive Cancer Center
A lung cancer sample showing CD14-positive regions in green, CCR2-positive regions in red, and pan-cytokeratin in aqua. Credit: UNC's Translational Pathology Lab.

University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.

In the journal Nature Communications, researchers report for a particular subset of tumors, there is a high prevalence of immune cells called inflammatory monocytes. These immune cells, which normally help to build clotting scaffolds to promote wound healing, also make it possible for cells to migrate and spread to other parts of the body.

"The way that these immune cells promote lung cancer metastases was very unexpected. They produce a large amount of a factor that leads to clot in the tumor, which the tumor cells can latch onto and climb across to spread in the body," said UNC Lineberger's Chad Pecot, MD, assistant professor in the UNC School of Medicine Division of Hematology and Oncology and the study's corresponding author. "Our goal is to use this information to teach the cancer 'wounds' to heal themselves."

Previous studies have classified lung squamous carcinoma—which accounts for about 30 percent of all lung cancers—into four different types based on their biological and molecular characteristics. In the new study, Pecot and his collaborators found that lung squamous carcinoma could be reclassified into just two different categories based on whether they showed a high presence of inflammatory monocytes.

They used expression of the CD14 gene as a biomarker to show that high presence of this immune cell was linked to poor survival.

"It's important to understand that while there is so much focus on activating parts of the immune system to attack cancer, there is also a 'Jekyll and Hyde' process going on in most tumors," Pecot said. "There are immune cells we want to activate, but there are other immune cells we want to turn off."

The researchers used newly developed laboratory models of lung squamous carcinoma to study the role of the inflammatory monocytes. The tumors make a signal called CCL2, which helps to recruit inflammatory monocytes. These then release a clotting factor, Factor XIIIA, which Pecot said creates a fibrin scaffold that climb across and then travel to distant organs.

"These results shed new light on tumor microenvironment functioning and, potentially, may lead to new approaches for targeting the metastases of this extremely aggressive disease," said Alessandro Porrello, Ph.D., researcher at UNC Lineberger and the study's first author.By genetically modifying the expression of CCL2 in a metastasis model developed in their laboratory, they found low expression was linked to reduced metastases, while high expression was linked to enhanced metastatic features. They also demonstrated that the presence of a clot made it easier for cancer to move and migrate. Also, when looking at tumor samples from patients, they found that tumors with high amounts of the fibrin cross-linking was associated with an increased risk of the tumor spreading.

The researchers were able to reduce metastases by using a compound that blocks CCR2, a receptor on the surface of the . They saw a significant decrease in lung metastases. Pecot said they want to continue investigating this strategy, and potentially other ways of preventing clotting within tumors, to see if it prevents metastases from initiating and whether it can stall the process once it has begun.

"We want to make progress for patients with lung squamous carcinoma and expand the therapeutic options available to these patients," Pecot said. "The more we understand the progression of the disease, including how metastases occurs, the more we'll be able to understand how we can regress this disease, or just keep it in check. We believe there are ways we can teach these tumors how to heal."

Explore further: For aggressive breast cancer in the brain, researchers clarify immune response

More information: Alessandro Porrello et al. Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking, Nature Communications (2018). DOI: 10.1038/s41467-018-04355-w

Related Stories

For aggressive breast cancer in the brain, researchers clarify immune response

April 17, 2018
Once it has begun to spread in the body, approximately half of patients with an aggressive breast cancer type will develop cancer in the brain. Researchers at the University of North Carolina Lineberger Comprehensive Cancer ...

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer

March 22, 2018
A study by Massachusetts General Hospital (MGH) investigators finds that, in mouse models, cancer cells from metastatic lymph nodes can escape into the circulation by invading nodal blood vessels, leading to the development ...

Tumor-associated neutrophils boost anti-tumor immune responses

November 11, 2014
Lung cancer is a leading cause of cancer-related deaths in both men and women, and survival depends on the stage of cancer at diagnosis. An inflammatory response is induced following tumor formation, and the immune cells ...

Researchers identify genetic 'seeds' of metastatic breast cancer

March 5, 2018
Breast cancer is the second leading cause of cancer death in women in the United States, with most deaths caused by the cancer spreading beyond the breast. In a new study, University of North Carolina Lineberger Comprehensive ...

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Communication between lung tumors and bones contributes to tumor progression

November 30, 2017
Massachusetts General Hospital (MGH) investigators have identified a way in which a type of lung cancer co-opts a portion of the immune system to increase tumor progression. In the Dec. 1 issue of Science, the team from the ...

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Scientists discover chemical which can kill glioblastoma cells

August 15, 2018
Aggressive brain tumour cells taken from patients self-destructed after being exposed to a chemical in laboratory tests, researchers have shown.

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.